KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Ratio (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Equity Ratio data on record, last reported at 0.28 in Q3 2025.

  • For Q3 2025, Equity Ratio rose 77.88% year-over-year to 0.28; the TTM value through Sep 2025 reached 0.28, up 77.88%, while the annual FY2024 figure was 0.2, 39.26% down from the prior year.
  • Equity Ratio reached 0.28 in Q3 2025 per NKTR's latest filing, up from 0.12 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.68 in Q1 2021 and bottomed at 0.12 in Q2 2025.
  • Average Equity Ratio over 5 years is 0.39, with a median of 0.4 recorded in 2023.
  • The widest YoY moves for Equity Ratio: up 77.88% in 2025, down 150.26% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.61 in 2021, then decreased by 15.17% to 0.52 in 2022, then crashed by 36.22% to 0.33 in 2023, then crashed by 39.26% to 0.2 in 2024, then surged by 41.25% to 0.28 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.28 in Q3 2025, 0.12 in Q2 2025, and 0.05 in Q1 2025.